Clinical Benefits of Memantine Treatment for Alzheimer's Disease in the Okayama Memantine Study II (OMS II)

Kosuke Matsuzono, Toru Yamashita, Yasuyuki Ohta, Nozomi Hishikawa, Makoto Koike, Kota Sato, Syoichiro Kono, Kentaro Deguchi, Yumiko Nakano, Koji Abe

Research output: Contribution to journalArticle

3 Citations (Scopus)


The clinical benefits of memantine, depending on the baseline cognitive and affective conditions in realworld dementia clinics, have not been completely examined. We performed the "Okayama Memantine Study II (OMS II)" to retrospectively evaluate the clinical effects of memantine monotherapy (n = 38) in Alzheimer's disease (AD) patients using seven batteries to assess dementia at the baseline, at 3, 6, and 12 months. Additionally, we divided 163 AD patients treated with memantine into two subgroups depending on the baseline cognitive score of the Mini-Mental State Examination (MMSE): the MMSE

Original languageEnglish
Pages (from-to)487-493
Number of pages7
JournalJournal of Alzheimer's Disease
Issue number2
Publication statusPublished - Jul 24 2015



  • Alzheimer's disease
  • behavioral and psychological symptoms of dementia
  • memantine
  • Mini-Mental State Examination
  • monotherapy

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Geriatrics and Gerontology
  • Clinical Psychology

Cite this